150 related articles for article (PubMed ID: 10092131)
1. Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas.
Simpson DJ; Bicknell JE; McNicol AM; Clayton RN; Farrell WE
Genes Chromosomes Cancer; 1999 Apr; 24(4):328-36. PubMed ID: 10092131
[TBL] [Abstract][Full Text] [Related]
2. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A/p16 inactivation is related to pituitary adenoma type and size.
Seemann N; Kuhn D; Wrocklage C; Keyvani K; Hackl W; Buchfelder M; Fahlbusch R; Paulus W
J Pathol; 2001 Apr; 193(4):491-7. PubMed ID: 11276008
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors.
Hibberts NA; Simpson DJ; Bicknell JE; Broome JC; Hoban PR; Clayton RN; Farrell WE
Clin Cancer Res; 1999 Aug; 5(8):2133-9. PubMed ID: 10473097
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis of pituitary tumors.
Farrell WE; Clayton RN
Front Neuroendocrinol; 2000 Jul; 21(3):174-98. PubMed ID: 10882539
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.
Ruebel KH; Jin L; Zhang S; Scheithauer BW; Lloyd RV
Endocr Pathol; 2001; 12(3):281-9. PubMed ID: 11740049
[TBL] [Abstract][Full Text] [Related]
7. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island.
Simpson DJ; Hibberts NA; McNicol AM; Clayton RN; Farrell WE
Cancer Res; 2000 Mar; 60(5):1211-6. PubMed ID: 10728677
[TBL] [Abstract][Full Text] [Related]
8. Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma.
Revill K; Dudley KJ; Clayton RN; McNicol AM; Farrell WE
Endocr Relat Cancer; 2009 Jun; 16(2):537-48. PubMed ID: 19218280
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas.
Simpson DJ; Magnay J; Bicknell JE; Barkan AL; McNicol AM; Clayton RN; Farrell WE
Cancer Res; 1999 Apr; 59(7):1562-6. PubMed ID: 10197629
[TBL] [Abstract][Full Text] [Related]
10. Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation.
Bahar A; Bicknell JE; Simpson DJ; Clayton RN; Farrell WE
Oncogene; 2004 Jan; 23(4):936-44. PubMed ID: 14647444
[TBL] [Abstract][Full Text] [Related]
11. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases.
Ai L; Stephenson KK; Ling W; Zuo C; Mukunyadzi P; Suen JY; Hanna E; Fan CY
Mod Pathol; 2003 Sep; 16(9):944-50. PubMed ID: 13679459
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
Farrell WE; Simpson DJ; Bicknell JE; Talbot AJ; Bates AS; Clayton RN
Cancer Res; 1997 Jul; 57(13):2703-9. PubMed ID: 9205080
[TBL] [Abstract][Full Text] [Related]
13. Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion.
Simpson DJ; Clayton RN; Farrell WE
Oncogene; 2002 Feb; 21(8):1217-24. PubMed ID: 11850841
[TBL] [Abstract][Full Text] [Related]
14. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables.
Vo QN; Geradts J; Boudreau DA; Bravo JC; Schneider BG
Hum Pathol; 2002 Dec; 33(12):1200-4. PubMed ID: 12514789
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary study of p16 gene expression in pituitary adenomas].
Yu WH; Hui GZ; Wang Q; Wu SR
Ai Zheng; 2003 Feb; 22(2):198-201. PubMed ID: 12600300
[TBL] [Abstract][Full Text] [Related]
17. P16 overexpression in pituitary adenomas studied by immunohistochemistry and in situ hybridization.
Yi J; Yu D; Chen Y; Xiong W; Li X; Shen J; Tang X
Chin Med J (Engl); 2000 Feb; 113(2):162-6. PubMed ID: 11775544
[TBL] [Abstract][Full Text] [Related]
18. Frequent p16 CpG island hypermethylation in primary remnant gastric cancer suggesting an independent carcinogenic pathway.
Mino A; Onoda N; Yashiro M; Aya M; Fujiwara I; Kubo N; Sawada T; Ohira M; Kato Y; Hirakawa K
Oncol Rep; 2006 Mar; 15(3):615-20. PubMed ID: 16465421
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
Chapman EJ; Harnden P; Chambers P; Johnston C; Knowles MA
Clin Cancer Res; 2005 Aug; 11(16):5740-7. PubMed ID: 16115911
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
